Abstract: ObjectiveTo investigate the effect of ticagrelor and clopidogrel on perioperative high sense C reactive protein(hsCRP) and shortterm efficacy and safety in patients with acute coronary syndrome(ACS) undergoing percutaneous coronary intervention(PCI). MethodsTotally 379 patients  with ACS  undergoing PCI  were randomized into ticagrilor group（n=189） and clopidogrel group（n=190）. Ticagrilor group（180 mg loading dose，90  mg maintanining dose，twice daily）and clopidogrel  group（600 mg loading dose，75 mg maintanining dose，once daily）. HsCRP and cTnI were detected in 24 hours before and after PCI procedure. All patients were followed up for  three  months，and adverse events were observed. ResultsThere were no significant difference in the baseline data between two groups. The ratio of hsCRP elevation after PCI in ticagrelor group was lower compared with that in clopidogrel group（33.3%  vs  63.6%，P<0.01）.There was no significant  difference in perioperative myocardial infarction  between two groups（15.3% vs  16.3%，P=0.796）. In the postoperative one month followup， the patients in ticagrelor group showed significantly lower MACCE rate compared with that in clopidogrel group（P=0.033）.There was no significant difference in bleeding events between two groups（P＞0.05）.ConclusionIn patients with ACS undergoing PCI， ticagrelor significantly reduces the elevation of hsCRP during PCI procedure  as compared with clopidogrel，which suggests ticagrelor significantly inhibits the inflammation in PCI procedure.

Key words: acute coronary syndrome；angioplasty, transluminal, percutaneous coronary；percutaneous coronary artery intervention；Creactive protein